Pay in 4 interest-free payments of $7.35 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Results After exclusions and propensity score trimming, the cohort consisted of 145 410 patients who started GLP1 receptor agonist treatment and 291 667 patients who started DPP4 inhibitor treatment (fig 1)
HR: 0.40, 95% CI: 0.290.56)
Approved uses : The Food and Drug Administration (FDA) has approved Jardiance and Farxiga for: Reducing the risk of heart-related death and hospitalization in adults with heart failure Decreasing the risk of declining kidney function, end-stage kidney disease, heart-related death, and hospitalization in adults with chronic kidney disease (CKD) at risk of progression Improving glycemic control in adults with type 2 diabetes as part of a diet and exercise plan Jardiance also reduces the risk of heart-related death in adults with type 2 diabetes and established heart disease
Environ Int 147:106321
Monthly bundled plans start at $129 (semaglutide) and $200 (tirzepatide) including the medication and physician visits
Synthesis plan A narrative synthesis of the included studies was conducted
